Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
TFCFA
Twenty-First Century Fox, Inc. Class A
TFCFA
|
+$327M |
| 2 |
Chipotle Mexican Grill
CMG
|
+$271M |
| 3 |
Chevron
CVX
|
+$264M |
| 4 |
JPMorgan Chase
JPM
|
+$233M |
| 5 |
Alphabet (Google) Class A
GOOGL
|
+$224M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$707M |
| 2 |
Johnson & Johnson
JNJ
|
+$396M |
| 3 |
Amazon
AMZN
|
+$312M |
| 4 |
Walmart Inc
WMT
|
+$285M |
| 5 |
Intuitive Surgical
ISRG
|
+$262M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 17.73% |
| 2 | Technology | 14.98% |
| 3 | Financials | 10.9% |
| 4 | Consumer Discretionary | 8.96% |
| 5 | Real Estate | 8.48% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
AFBI
2901
DELISTED
Affinity Bancshares
AFBI
| $428K | ﹤0.01% |
33,158
+6,431
| +24% | +$82.1K |
|
|
CYAN
2902
DELISTED
Cyanotech Corp
CYAN
| $427K | ﹤0.01% |
127,600
-2,400
| -2% | -$8.89K |
|
|
AMRS
2903
DELISTED
Amyris Inc.
AMRS
| $427K | ﹤0.01% |
53,783
+27,700
| +106% | +$204K |
|
|
PLYM
2904
DELISTED
Plymouth Industrial REIT
PLYM
| $426K | ﹤0.01% |
+27,470
| New | +$432K |
|
|
MMAC
2905
DELISTED
MMA Capital Holdings, Inc. Common Stock
MMAC
| $426K | ﹤0.01% |
16,278
-3,315
| -17% | -$88.5K |
|
2906
AdvanSix
ASIX
$427M
| $424K | ﹤0.01% |
+12,500
| New | +$449K |
|
|
DFBG
2907
DELISTED
Differential Brands Group Inc
DFBG
| $423K | ﹤0.01% |
104,183
+42,401
| +69% | +$203K |
|
|
SRNE
2908
DELISTED
Sorrento Therapeutics, Inc.
SRNE
| $422K | ﹤0.01% |
95,916
-255,347
| -73% | -$1.42M |
|
2909
AC Immune
ACIU
$267M
| $418K | ﹤0.01% |
52,300
+29,720
| +132% | +$299K |
|
2910
iShares MSCI EAFE Small-Cap ETF
SCZ
$13.6B
| $417K | ﹤0.01% |
+6,700
| New | +$418K |
|
2911
First United
FUNC
$294M
| $412K | ﹤0.01% |
21,900
-10,380
| -32% | -$202K |
|
2912
Scully Royalty
SRL
$90.9M
| $412K | ﹤0.01% |
67,570
-11,700
| -15% | -$73.9K |
|
|
CRT
2913
Cross Timbers Royalty Trust
CRT
$60.6M
| $411K | ﹤0.01% |
27,836
-10,510
| -27% | -$157K |
|
2914
Mid Penn Bancorp
MPB
$969M
| $411K | ﹤0.01% |
14,100
-1,000
| -7% | -$31.7K |
|
2915
Vanguard Morningstar Mid-Cap ETF
VO
$111B
| $410K | ﹤0.01% |
10,000
-2,800
| -22% | -$114K |
|
2916
Traws Pharma
TRAW
$8.12M
| $410K | ﹤0.01% |
149
+3
| +2% | +$7.65K |
|
2917
Vanguard S&P Mid-Cap 400 ETF
IVOO
$3.95B
| $408K | ﹤0.01% |
6,000
+800
| +15% | +$54.3K |
|
2918
Merchants Bancorp
MBIN
$2.52B
| $408K | ﹤0.01% |
+24,087
| New | +$431K |
|
2919
Electromed
ELMD
$352M
| $405K | ﹤0.01% |
62,300
+20,600
| +49% | +$111K |
|
2920
Sensus Healthcare
SRTS
$51.5M
| $403K | ﹤0.01% |
48,100
+20,612
| +75% | +$149K |
|
|
SBBP
2921
DELISTED
Strongbridge Biopharma plc.
SBBP
| $402K | ﹤0.01% |
82,800
-89,600
| -52% | -$458K |
|
|
MNI
2922
DELISTED
The McClatchy Company Class A Common Stock
MNI
| $402K | ﹤0.01% |
47,230
+2,600
| +6% | +$24.2K |
|
|
STRM
2923
DELISTED
Streamline Health Solutions
STRM
| $400K | ﹤0.01% |
22,627
-413
| -2% | -$7.89K |
|
2924
ClearOne Inc
CLRO
$15.2M
| $399K | ﹤0.01% |
12,105
+2,628
| +28% | +$110K |
|
|
LOMA
2925
Loma Negra
LOMA
$1.13B
| $399K | ﹤0.01% |
+45,100
| New | +$429K |
|
Similar funds
Jim Simons's Q3 2018 Portfolio in Review
As of Q3 2018, Jim Simons held 3,734 positions worth $97.3B, up 6% from $91.7B the previous quarter. Its ten largest holdings account for 9.7% of the portfolio.
Jim Simons's Q3 2018 filing shows 508 new, 1,623 increased, 1,169 reduced and 410 closed positions. Its largest new stake was JPMorgan Chase: 2,054,913 shares worth $232M. The largest sale was Apple, an estimated $707M.
By sector, the portfolio is most concentrated in Healthcare at 18% of assets, up from 18% a quarter earlier, followed by Technology and Financials.
- Jim Simons's largest Q3 2018 buy was JPMorgan Chase: 2,054,913 shares worth $232M.
- Jim Simons added most to Twenty-First Century Fox, Inc. Class A in Q3 2018, an estimated $327M increase.
- Jim Simons's biggest Q3 2018 reduction was Johnson & Johnson, cutting an estimated $396M.
- Jim Simons fully exited Apple in Q3 2018, selling an estimated $707M.
- Jim Simons's ten largest holdings make up 9.7% of its $97.3B portfolio in Q3 2018.
- Jim Simons opened 508 new positions and closed 410 in Q3 2018.
- Jim Simons's portfolio value rose 6% quarter-over-quarter to $97.3B.
Based on Renaissance Technologies's 13F filing for Q3 2018, filed 13 Nov 2018.